CMR Surgical
Healthcare Access & Wellbeing
Transforming surgery with a next-generation surgical robot.
Impact Rating
Transforming surgery with a next-generation surgical robot.
Company Overview
CMR Surgical operates as a surgical robotics company developing universal robotic systems for minimal access surgery. It aims to make minimal-access surgery universally accessible and affordable by expanding the range of procedures that can be performed robotically. Versius is designed to give surgeons and hospitals the versatility to operate in the way that’s best for patients and to maximise utilisation.
CMR Surgical's Impact
CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally available and inexpensive.
Core Mission and Values
CMR Surgical’s mission is serious and ambitious, working in a culture of openness, responsibility and fun. Showing respect to one another is at the core of CMR’s values and it is an essential element of an enjoyable and productive working environment. All in all, their goal is to empower surgeons, surgical teams and hospitals to transform how surgery is performed around the world.
Current Investors
Investors include Chimera Capital, Ally Bridge Group, Escala Capital Ventures, GE Healthcare.
Leadership & Team
Supratim Bose
CEO
Supratim, a medical technology industry expert with extensive experience, has held senior leadership positions in global MedTech organisations like ConvaTec and Boston Scientific. Throughout his career, Supratim has been recognised within the industry for his ability to drive growth, expand market reach, and improve operational efficiency in organisations he has served.
Anna Wasyl
CFO
Anna has held senior leadership positions at ABB, a leading manufacturer of industrial robots, and has led finance functions in the Chinese market. Anna has a proven track record in leading complex changes and collaboration across cultures.
Mark Slack
Chief Medical Officer
Mark, a South African medical doctor and Gynaecologist, has a combined clinical and academic career, focusing on surgery, gynaecology, and basic science research.
Marcio Coelho
Chief Commercial Officer
Marcio, a global executive with experience at Johnson & Johnson and Becton & Dickinson, has led large business units and regional organizations across the US, EMEA, and Latin America. He has successfully managed accelerated growth, turnarounds, and acquisition integrations.
How are CMR Surgical using funds raised?
The funds will be used to increase the global commercialisation of Versius, CMR’s next-generation surgical robotic system, and further develop its digital ecosystem. The funds have provided the financing to fully execute CMR’s strategy to rapidly accelerate its geographical expansion and builds upon the framework the company has established to grow a long-term independent global business. The new funds also support the continued development of the system’s digital framework, including new technological developments such as Versius Connect, an app for surgeons using the Versius surgical robotic system.
How are CMR Surgical driving innovation?
Versius captures meaningful data with its wider digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.
Research by: Bilal Ismail
Latest News in Life Sciences
08/23/25, 08:48 PM
SRPT FINAL DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline in Securities Class Action - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 23, 2025 ( GLOBE NEWSWIRE ) -- A securities class-action lawsuit is underway against Sarepta Therapeutics SRPT, triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ...
Source: Benzinga
Read more →08/23/25, 02:00 PM
MONDAY INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
MONDAY INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ...
Source: Business Insider
Read more →08/23/25, 01:45 PM
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS - Hims & Hers Health ( NYSE:HIMS )
SAN DIEGO, Aug. 23, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc.
Source: Benzinga
Read more →